Gilead saves US$10b in taxes as pricey hep C drug takes off
This boosts its already huge profits, letting firm stash even more billions in tax havens abroad, says advocacy group
New York
GILEAD Sciences Inc's profit margin has soared and its tax rate has plummeted since the drugmaker introduced its controversial US$1,000-a- day medication for hepatitis C, according to a report by an advocacy group that accuses the company of using accounting gimmicks to stash billions in earnings in tax havens offshore.
By moving some of its intellectual property to Ireland, Gilead was able to employ a common strategy that cut its US tax bill by US$10 billion since 2013, according to Americans for Tax Fairness (ATF), a left-leaning think-tank.
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
Consumer & Healthcare
Wall Street Journal moves Asia headquarters from Hong Kong to Singapore
South Korea to slap fines on food suppliers for ‘shrinkflation’
Olam outbids Dreyfus’ sweetened deal for Australia’s Namoi, raises offer to A$0.66 per share
Live Nation’s revenue beats estimates as boom in concerts drive ticket sales
Jim Beam owner bets on canned vodka cocktails to double revenue
Cutting the cord?: Events leading up to Cordlife’s MOH suspension and arrests of its directors, ex-group CEO